- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Gastrointestinal stromal tumour
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1133KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 115KB)
Ripretinib – July 2021
Ripretinib: Tablet 50 mg; Qinlock®
Last updated
29 October 2021